Fineline Cube

Follow:
14855 Articles
AstraZeneca Proposes ~US$10 Billion Acquisition of Obesity Drugmaker Rhythm Pharmaceuticals – Deal to Be Pursued Through Rare Disease Unit Alexion
CompanyDeals

AstraZeneca Proposes ~US$10 Billion Acquisition of Obesity Drugmaker Rhythm Pharmaceuticals – Deal to Be Pursued Through Rare Disease Unit Alexion

Immunochina's IM19 Wins NMPA Approval – First Fully In‑House CD19 CAR‑T Cell Therapy for Relapsed or Refractory Large B‑Cell Lymphoma in China
CompanyDrug

Immunochina’s IM19 Wins NMPA Approval – First Fully In‑House CD19 CAR‑T Cell Therapy for Relapsed or Refractory Large B‑Cell Lymphoma in China

Eisai and Meituan Healthcare Sign Instant Retail Partnership at CIIE – Dayvigo 14‑Tablet Pack Powers "Order at Night, Delivered Nearby" Sleep Health Ecosystem
CompanyDeals

Eisai and Meituan Healthcare Sign Instant Retail Partnership at CIIE – Dayvigo 14‑Tablet Pack Powers “Order at Night, Delivered Nearby” Sleep Health Ecosystem

Bio‑Thera's BAT2506 Wins NMPA Approval – First Golimumab Biosimilar in China for Rheumatoid Arthritis and Ankylosing Spondylitis
CompanyDrug

Bio‑Thera’s BAT2506 Wins NMPA Approval – First Golimumab Biosimilar in China for Rheumatoid Arthritis and Ankylosing Spondylitis

Fosun Pharma Advances Two Pipeline Programs – FXS6837 Enters Phase III for PNH in China as IL1RAP Antibody HLX109 Clears Phase I in Australia
CompanyDrug

Fosun Pharma Advances Two Pipeline Programs – FXS6837 Enters Phase III for PNH in China as IL1RAP Antibody HLX109 Clears Phase I in Australia

Johnson & Johnson's Rybrevant Faspro Wins FDA Accelerated Approval – First Dual‑Target EGFR–MET Therapy for Pretreated HNSCC
CompanyDrug

Johnson & Johnson’s Rybrevant Faspro Wins FDA Accelerated Approval – First Dual‑Target EGFR–MET Therapy for Pretreated HNSCC

IASO Bio Partners with Shenzhen Longuide to Deploy LNP Technology Beyond Oncology – Broadening the Cell Therapy Innovator's Advanced Therapeutics Portfolio
CompanyDeals

IASO Bio Partners with Shenzhen Longuide to Deploy LNP Technology Beyond Oncology – Broadening the Cell Therapy Innovator’s Advanced Therapeutics Portfolio

China's NHC Issues Working Procedures for Rare Disease Catalogue (2026 Edition) – Expanded Inclusion Criteria and Faster Update Cycle Reshape Drug Access Landscape
Policy / Regulatory

China’s NHC Issues Working Procedures for Rare Disease Catalogue (2026 Edition) – Expanded Inclusion Criteria and Faster Update Cycle Reshape Drug Access Landscape

Nxera Pharma Licenses Oral EP4 Agonist NXE0033744 to AbbVie in up to USD 1.47 Billion IBD Deal – Validating the NxWave Discovery Platform
CompanyDeals

Nxera Pharma Licenses Oral EP4 Agonist NXE0033744 to AbbVie in up to USD 1.47 Billion IBD Deal – Validating the NxWave Discovery Platform

Shanghai Henlius Advances Anti‑IL1RAP Antibody HLX109 Toward First‑in‑Human Trial – Australian HREC Approval and TGA CTN Completed for Generalized Pustular Psoriasis
CompanyDrug

Shanghai Henlius Advances Anti‑IL1RAP Antibody HLX109 Toward First‑in‑Human Trial – Australian HREC Approval and TGA CTN Completed for Generalized Pustular Psoriasis

Hybio Pharmaceutical's HY3003 Clears FDA IND – Triple GLP‑1R/GIPR/GCGR Agonist Advances Toward the Obesity Market
CompanyDrug

Hybio Pharmaceutical’s HY3003 Clears FDA IND – Triple GLP‑1R/GIPR/GCGR Agonist Advances Toward the Obesity Market

Hinova Licenses Oral VAV1 Molecular Glue Degrader HP570 to Evommune in Up to USD 1.1 Billion Deal – Days After FDA IND Clearance for Rheumatoid Arthritis
CompanyDeals

Hinova Licenses Oral VAV1 Molecular Glue Degrader HP570 to Evommune in Up to USD 1.1 Billion Deal – Days After FDA IND Clearance for Rheumatoid Arthritis